Asset Details
Do you wish to reserve the book?
Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn’s Disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn’s Disease
Do you wish to request the book?
Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn’s Disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn’s Disease
2015
Overview
The chronic inflammation of Crohn's disease is caused, at least in part, by repression of TGF-β1 signaling, which is caused by high levels of SMAD7. This trial shows that mongersen, an antisense inhibitor of
SMAD7
mRNA, induces disease remission in some persons.
Crohn’s disease is a chronic inflammatory illness that primarily affects the terminal ileum and right colon. Crohn’s disease–related inflammation is segmental and transmural, leading to various degrees of tissue damage.
1
At disease onset, most patients have inflammatory lesions, which become predominantly strictures or penetrating lesions over time.
2
,
3
Mucosal healing can be promoted with the use of immunosuppressive drugs and anti–tumor necrosis factor
α
(TNF-
α
) antibodies; however, more than one third of patients do not have a response to these therapies. The efficacy of these drugs may also diminish over time, and they can increase a patient’s risk . . .
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Aged
/ C-Reactive Protein - analysis
/ Crohn Disease - drug therapy
/ Dose-Response Relationship, Drug
/ Female
/ Glucocorticoids - administration & dosage
/ Humans
/ Immunosuppressive Agents - administration & dosage
/ Immunosuppressive Agents - adverse effects
/ Male
/ Oligonucleotides - administration & dosage
/ Oligonucleotides - adverse effects
/ Oligonucleotides, Antisense - therapeutic use
/ Patients
/ Smad7 Protein - antagonists & inhibitors
